Dhanunjaya Tamatam

Managing Director

India’s thriving pharmaceuticals sector presents a promising landscape for existing and upcoming businesses to introduce advanced medications. The intensely competitive domain is encouraging innovation, while simultaneously providing opportunities for emerging and existing players to introduce affordable yet high quality products to domestic patients. At the same time, India’s position as a leading exporter of generic medications, as well as generic injectables offers players the opportunity to export high-quality products. Tightening quality and regulatory standards, however, pose a significant challenge as companies need to continually evolve to meet new compliance norms to flourish.

Within this domain, French Biologicals Pvt. Ltd., a Hyderabad-based firm established in 2017 has grown into a leading pharma startup, specializing in manufacturing critical care and nephrology products including injectables and tablets, in association with WHO-GMP certified manufacturing plants. Standing out for its commitment to producing high quality products and making them available at affordable prices, the company is taking the pharma sector in India by storm.

Extensive Range of Products

The pharmaceuticals sector is advancing rapidly in India, with new formulations and treatment options for challenges like dialysis being discovered. Moving from traditional medications and formulations to more advanced and effective ones, medical experts are paving the way for enhanced treatment of critical illnesses. French Biologicals is dedicated to keeping up with these changes efficiently, by innovating new products that cater to the needs of nephrology and critical care domains.

The company produces a wide range of products encompassing injectables such as Inj Carnit, Mero-French, iv Fero-French, Vancofrench, and Zidifrench-S, as well as tablets like Ketofrench, Mycofrench, Biofrench, NefroPlus, Gio D3 Plus, and FrenoSev-Act. These distinctive drugs have been designed meticulously for greater efficacy, putting the firm in a stable position as a trusted partner in the industry, and enabling its growth over the years.

Advancing with the evolving demands of the sector, French Biologicals has not only expanded its presence from Hyderabad to cover the entire South Indian region and key parts across North and East India, but also introduced unique new formulations that effectively address critical and nephrology concerns. Moreover, the company also shifted from the market patterns of providing certain drugs in multi-pack configurations, and introduced then instead in single or ‘mono carton’ packaging options, making them much more useful, and preferred in the market.

“When we started our company, the first two years proved to be quite challenging, and presented a learning opportunity for us. Gradually, we reformed our approach in the marketplace, added more products in our basket, and slowly increased business. We continued to make changes as per the market dynamics, and continued to enhance our product range which propelled our growth. We have introduced two unique combinations of two different molecules with all approvals that established the validity of our products. It took us two years to reach our goal, but it enabled us to gain widespread recognition”, shares Dhanunjaya Tamatam, Founder & CEO, French Biologicals.

Working closely with hospitals, the company, leveraging the skilled workforce that it houses, strives to understand the current needs of the patients, and provides drug options that fulfill these needs to the healthcare facilities. Beyond the ability to offer targeted products of the highest quality, exceeding industry standards, the company also stands out for the attention to detail in packaging, and it's guaranteed on time delivery.

Growth and Future Vision

Led by a dynamic team consisting of the founder who brings in over twenty-three years of experience in the pharma industry, having worked with prominent domestic companies and MNCs, along with an experienced Board of Directors, including T. Lavanya, who brings twelve years of experience in the pharmaceuticals sector and is also the MD and Founder of Paramount Health Care, another company belonging to the French Biologicals family, the company has big aspirations and plans for its future growth.

Having overcome a range of challenges, French Biologicals has gained critical insights in thriving in the pharmaceuticals domain, and has developed an agile approach, which is driving the firm to adapt and grow in this dynamic field. Over the past five years, the firm has worked relentlessly to expand its operations across the entirety of South India, and has successfully achieved this goal. Moreover, it has also deployed field staff across Delhi, Kolkata, and Uttar Pradesh and developed itself as a key supplier, with an annual rate contract.

As the firm moves forward, it remains dedicated to fulfilling its vision of becoming a leading supplier of high quality products at an affordable price that is suitable for all segments, ensuring that financial strength does not bar anyone from gaining the best healthcare resources. While ensuring this, the company aims to grow and expand further, by collaborating with promoters and investors that can elevate the firm’s position pan India, and on the global scale. Moreover, the firm also plans to export its products to key markets in the coming years, seizing all opportunities for growth, and becoming a globally preferred partner of choice in the pharmaceuticals domain.